| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Na Li, Mengdi Li, Minfang Guo, Tao Meng, Bingtao Mu, Jingwen Yu, Jiwei Wang, Lijuan Song, Cungen Ma, Jiezhong We. [Eriodictyol improves cognitive function in 5×FAD mice of Alzheimer's disease by inhibiting the microglia NLRP3 inflammasome signaling pathway]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology. vol 39. issue 11. 2023-11-19. PMID:37980548. |
[eriodictyol improves cognitive function in 5×fad mice of alzheimer's disease by inhibiting the microglia nlrp3 inflammasome signaling pathway]. |
2023-11-19 |
2023-11-20 |
mouse |
| Na Li, Mengdi Li, Minfang Guo, Tao Meng, Bingtao Mu, Jingwen Yu, Jiwei Wang, Lijuan Song, Cungen Ma, Jiezhong We. [Eriodictyol improves cognitive function in 5×FAD mice of Alzheimer's disease by inhibiting the microglia NLRP3 inflammasome signaling pathway]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology. vol 39. issue 11. 2023-11-19. PMID:37980548. |
objective to investigate the therapeutic effects of eriodictyol on transgenic mice with five familial alzheimer's disease (5×fad) and the modulation of nod-like receptor-pyrin domain containing 3 (nlrp3) inflammasome in microglia. |
2023-11-19 |
2023-11-20 |
mouse |
| Shuqi Tao, Wenyuan Fan, Jinmeng Liu, Tong Wang, Haoning Zheng, Gaoxiu Qi, Yanchun Chen, Haoyun Zhang, Zhangyu Guo, Fenghua Zho. NLRP3 Inflammasome: An Emerging Therapeutic Target for Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2023-11-19. PMID:37980662. |
nlrp3 inflammasome: an emerging therapeutic target for alzheimer's disease. |
2023-11-19 |
2023-11-29 |
human |
| Helena Neudorf, Jonathan P Littl. Impact of fasting & ketogenic interventions on the NLRP3 inflammasome: A narrative review. Biomedical journal. 2023-11-08. PMID:37940045. |
overactivation of the nlrp3 inflammasome is implicated in chronic low-grade inflammation associated with various disease states, including obesity, type 2 diabetes, atherosclerosis, alzheimer's disease, and parkinson's disease. |
2023-11-08 |
2023-11-20 |
human |
| David Harrison, Andy Billinton, Mark G Bock, John R Doedens, Christopher A Gabel, M Katharine Holloway, Roderick A Porter, Valérie Reader, Jane Scanlon, Kenneth Schooley, Alan P Wat. Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders. Journal of medicinal chemistry. 2023-10-24. PMID:37874905. |
neurodegenerative disorders, including alzheimer's disease, parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis, have been shown to have a component driven by nlrp3 inflammasome activation. |
2023-10-24 |
2023-11-08 |
Not clear |
| Ahmed F Abdel-Magi. The Potential of NOD-like Receptor Protein 3 Inflammasome Inhibitors in the Treatments of Diseases. ACS medicinal chemistry letters. vol 14. issue 10. 2023-10-18. PMID:37849533. |
these compounds are inhibitors of the nod-like receptor protein 3 (nlrp3) inflammasome pathway and may potentially provide a useful treatment for one or more of the diseases and disorders mediated by nlrp3, including but not limited to immune diseases, inflammatory diseases, autoimmune diseases, autoinflammatory fever syndromes, cryopyrin-associated periodic syndrome, chronic liver disease, kidney-related disease, hyperoxaluria, lupus nephritis, type i and type ii diabetes, nephropathy, neurodegenerative diseases, alzheimer's disease, cardiovascular diseases, metabolic diseases and many more. |
2023-10-18 |
2023-11-08 |
Not clear |
| Guang-Zhi Liu, Tian-Tong Niu, Qian Yu, Bao-Lei Xu, Xiao-Qing Li, Bo-Yi Yuan, Guo-Bin Yuan, Ting-Ting Yang, Hui-Qin Li, Yi Su. Ginkgolide attenuates memory impairment and neuroinflammation by suppressing the NLRP3/caspase-1 pathway in Alzheimer's disease. Aging. vol 15. 2023-10-04. PMID:37793010. |
the nlrp3 inflammasome is involved in the neuroinflammatory pathway of alzheimer's disease (ad). |
2023-10-04 |
2023-10-07 |
mouse |
| Yue-Ran Jia, Zi-Qing Guo, Qian Guo, Xiao-Chuan Wan. Glycogen Synthase Kinase-3β, NLRP3 Inflammasome, and Alzheimer's Disease. Current medical science. 2023-09-18. PMID:37721665. |
glycogen synthase kinase-3β, nlrp3 inflammasome, and alzheimer's disease. |
2023-09-18 |
2023-10-07 |
Not clear |
| Rumaiza Mamsa, Kedar S Prabhavalkar, Lokesh Kumar Bhat. Crosstalk between NLRP3 inflammasome and calpain in Alzheimer's disease. The European journal of neuroscience. 2023-08-31. PMID:37652164. |
crosstalk between nlrp3 inflammasome and calpain in alzheimer's disease. |
2023-08-31 |
2023-09-07 |
Not clear |
| Rumaiza Mamsa, Kedar S Prabhavalkar, Lokesh Kumar Bhat. Crosstalk between NLRP3 inflammasome and calpain in Alzheimer's disease. The European journal of neuroscience. 2023-08-31. PMID:37652164. |
calpains and nod-like receptor protein-3 (nlrp3) inflammasomes are involved in the neuroinflammatory pathway and affect the progression of alzheimer's disease. |
2023-08-31 |
2023-09-07 |
Not clear |
| Meibo Duan, Lei Sun, Xinzi He, Zechen Wang, Yunlei Hou, Yanfang Zha. Medicinal chemistry strategies targeting NLRP3 inflammasome pathway: A recent update from 2019 to mid-2023. European journal of medicinal chemistry. vol 260. 2023-08-28. PMID:37639823. |
inhibiting nlrp3 has been widely studied as therapeutics for the treatment of cryopyrin associated periodic syndrome (caps), inflammatory bowel disease (ibd), nonalcoholic steatohepatitis (nash), arthrolithiasis, alzheimer's disease (ad) and parkinson's disease (pd). |
2023-08-28 |
2023-09-07 |
Not clear |
| Ram W Sabni. Pyridazine Derivatives as NLRP3 Inhibitors for Treating Asthma, COPD, Parkinson's Disease, and Alzheimer's Disease. ACS medicinal chemistry letters. vol 14. issue 8. 2023-08-16. PMID:37583813. |
pyridazine derivatives as nlrp3 inhibitors for treating asthma, copd, parkinson's disease, and alzheimer's disease. |
2023-08-16 |
2023-09-07 |
Not clear |
| Ram W Sabni. Pyridazine Derivatives as NLRP3 Inhibitors for Treating Asthma, COPD, Parkinson's Disease, and Alzheimer's Disease. ACS medicinal chemistry letters. vol 14. issue 8. 2023-08-16. PMID:37583813. |
provided herein are novel pyridazine derivatives as nlrp3 inhibitors, pharmaceutical compositions, use of such compounds in treating asthma, copd, parkinson's disease, and alzheimer's disease, and processes for preparing such compounds. |
2023-08-16 |
2023-09-07 |
Not clear |
| He Sun, Dandan Xiao, Wei Liu, Xue Li, Zhe Lin, Yong Li, Yuling Din. Well-known polypeptides of deer antler velvet with key actives: modern pharmacological advances. Naunyn-Schmiedeberg's archives of pharmacology. 2023-08-09. PMID:37555852. |
the results showed that deer antler polypeptides (daps), by regulating egf, egfr, mapk, p38, erk, nf-κb, wnt, pi3k, akt, mmp, ampk, stir1, nlrp3, ho-1, nrf, rho, tlr, tgf-β, smad, ang ii, etc., revealed their effects on seven system-related diseases and their mechanisms, including osteoarthritis, intervertebral disc degeneration, osteoporosis, alzheimer's, parkinson's, triple-negative breast cancer, liver injury, liver fibrosis, cardiovascular disease, acute lung injury, and late-onset hypogonadism. |
2023-08-09 |
2023-08-16 |
Not clear |
| Ying Chen, Xingyan Ye, Germaine Escames, Wangrui Lei, Xin Zhang, Meng Li, Tong Jing, Yu Yao, Zhenye Qiu, Zheng Wang, Darío Acuña-Castroviejo, Yang Yan. The NLRP3 inflammasome: contributions to inflammation-related diseases. Cellular & molecular biology letters. vol 28. issue 1. 2023-06-27. PMID:37370025. |
multiple studies have demonstrated the importance of the nlrp3 inflammasome in the development of immune and inflammation-related diseases, including arthritis, alzheimer's disease, inflammatory bowel disease, and other autoimmune and autoinflammatory diseases. |
2023-06-27 |
2023-08-14 |
Not clear |
| Sung Hoon Baik, V Krishnan Ramanujan, Courtney Becker, Sarah Fett, David M Underhill, Andrea J Wol. Hexokinase dissociation from mitochondria promotes oligomerization of VDAC that facilitates NLRP3 inflammasome assembly and activation. Science immunology. vol 8. issue 84. 2023-06-16. PMID:37327321. |
nlrp3 inflammasome activation is a highly regulated process for controlling secretion of the potent inflammatory cytokines il-1β and il-18 that are essential during bacterial infection, sterile inflammation, and disease, including colitis, diabetes, alzheimer's disease, and atherosclerosis. |
2023-06-16 |
2023-08-14 |
Not clear |
| Hong Ni, Jiaoqi Ren, Qimeng Wang, Xing Li, Yue Wu, Dezhi Liu, Jie Wan. Electroacupuncture at ST 36 ameliorates cognitive impairment and beta-amyloid pathology by inhibiting NLRP3 inflammasome activation in an Alzheimer's disease animal model. Heliyon. vol 9. issue 6. 2023-06-09. PMID:37292305. |
electroacupuncture at st 36 ameliorates cognitive impairment and beta-amyloid pathology by inhibiting nlrp3 inflammasome activation in an alzheimer's disease animal model. |
2023-06-09 |
2023-08-14 |
mouse |
| Shahrzad Nazari, Seyed Mahmoud Pourmand, Elahe Motevaseli, Gholamreza Hassanzade. Mesenchymal stem cells (MSCs) and MSC-derived exosomes in animal models of central nervous system diseases: Targeting the NLRP3 inflammasome. IUBMB life. 2023-06-06. PMID:37278718. |
the nlrp3 inflammasome has been implicated in the pathogenesis of many disorders affecting the central nervous system (cns), ranging from stroke, traumatic brain injury, and spinal cord injury to alzheimer's disease, parkinson's disease, epilepsy, multiple sclerosis, and depression. |
2023-06-06 |
2023-08-14 |
Not clear |
| b' Anna Chiarini, Li Gui, Chiara Viviani, Ubaldo Armato, Ilaria Dal Pr\\xc3\\xa. NLRP3 Inflammasome\'s Activation in Acute and Chronic Brain Diseases-An Update on Pathogenetic Mechanisms and Therapeutic Perspectives with Respect to Other Inflammasomes. Biomedicines. vol 11. issue 4. 2023-05-16. PMID:37189617.' |
second, we pinpoint nlrp3-activating mechanisms and known nlrp3 inhibition effects in acute (ischemia, stroke, hemorrhage), chronic (alzheimer's disease, parkinson's disease, huntington's disease, ms, als), and virus-induced (zika, sars-cov-2, and others) human brain diseases. |
2023-05-16 |
2023-08-14 |
human |
| Liu Liu, Linxiang Feng, Jiahui Gao, Jie Hu, Ang Li, Yangyang Zhu, Changlong Zhang, Bensheng Qiu, Zuojun She. Parthenolide targets NLRP3 to treat inflammasome-related diseases. International immunopharmacology. vol 119. 2023-05-11. PMID:37167640. |
acting as the most studied inflammasome, nlrp3 inflammasome played an important role in human diseases including type-2 diabetes (t2d), alzheimer's disease (ad) and cryopyrin-associated periodic syndromes (caps). |
2023-05-11 |
2023-08-14 |
mouse |